Mesenkia Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Mesenkia Therapeutics is a Swedish pre-clinical biotech company developing first-in-class, single-domain antibody (VHH) therapeutics targeting glioblastoma. Its core technology is based on a novel HVEM antagonistic antibody platform, originating from decades of foundational research by its renowned scientific founders. The company is advancing its lead asset, HV01, towards clinical development, supported by strong academic ties, recent patent allowances, and investment from Almi Invest. Mesenkia aims to address the high unmet clinical need in brain cancer by increasing treatment efficacy and patient quality of life.

OncologyNeuro-oncology

Technology Platform

Platform for developing single-domain antibodies (VHH) targeting the HVEM signaling pathway for the treatment of glioblastoma.

Opportunities

The significant unmet medical need in glioblastoma, with poor survival rates and limited treatment options, creates a large and growing market.

The novel HVEM target and single-domain antibody format offer potential for first-in-class, differentiated therapies with improved brain penetration.

Rising pharma interest in neuro-oncology enhances partnership and exit potential.

Risk Factors

High risk of failure inherent in pre-clinical and clinical drug development, particularly for a novel target in a complex disease like glioblastoma.

Dependency on securing additional funding to advance to and through costly clinical trials.

Potential future competition from other modalities and targets in the neuro-oncology space.

Competitive Landscape

The glioblastoma treatment landscape is active with ongoing research into various modalities including targeted therapies, immunotherapies, and novel delivery systems. Mesenkia's primary competition comes from other companies developing biologics and targeted agents for GBM. Its key differentiators are the novel HVEM target and the potential advantages of the single-domain antibody (VHH) platform for CNS penetration.

More companies in Biologics / Biosimilars →More companies in Sweden →